JP2011511073A5 - - Google Patents

Download PDF

Info

Publication number
JP2011511073A5
JP2011511073A5 JP2010545884A JP2010545884A JP2011511073A5 JP 2011511073 A5 JP2011511073 A5 JP 2011511073A5 JP 2010545884 A JP2010545884 A JP 2010545884A JP 2010545884 A JP2010545884 A JP 2010545884A JP 2011511073 A5 JP2011511073 A5 JP 2011511073A5
Authority
JP
Japan
Prior art keywords
carbon atoms
acid
group
alkyl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010545884A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011511073A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/000771 external-priority patent/WO2009099650A2/en
Publication of JP2011511073A publication Critical patent/JP2011511073A/ja
Publication of JP2011511073A5 publication Critical patent/JP2011511073A5/ja
Pending legal-status Critical Current

Links

JP2010545884A 2008-02-07 2009-02-06 Tlr7活性化物質による膀胱の疾患の治療 Pending JP2011511073A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2699908P 2008-02-07 2008-02-07
PCT/US2009/000771 WO2009099650A2 (en) 2008-02-07 2009-02-06 Treatment of bladder diseases with a tlr7 activator

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014079326A Division JP2014129425A (ja) 2008-02-07 2014-04-08 Tlr7活性化物質による膀胱の疾患の治療

Publications (2)

Publication Number Publication Date
JP2011511073A JP2011511073A (ja) 2011-04-07
JP2011511073A5 true JP2011511073A5 (enExample) 2012-03-15

Family

ID=40939077

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010545884A Pending JP2011511073A (ja) 2008-02-07 2009-02-06 Tlr7活性化物質による膀胱の疾患の治療
JP2014079326A Pending JP2014129425A (ja) 2008-02-07 2014-04-08 Tlr7活性化物質による膀胱の疾患の治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014079326A Pending JP2014129425A (ja) 2008-02-07 2014-04-08 Tlr7活性化物質による膀胱の疾患の治療

Country Status (12)

Country Link
US (1) US20090202626A1 (enExample)
EP (1) EP2259788A4 (enExample)
JP (2) JP2011511073A (enExample)
KR (1) KR20100137449A (enExample)
CN (1) CN102088974A (enExample)
AU (1) AU2009210655B2 (enExample)
BR (1) BRPI0907907A2 (enExample)
CA (1) CA2713438A1 (enExample)
EA (1) EA201001264A1 (enExample)
IL (1) IL207246A0 (enExample)
MX (1) MX2010008697A (enExample)
WO (1) WO2009099650A2 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2620182A1 (en) 2005-08-22 2007-03-01 Dennis A. Carson Tlr agonists
WO2007142755A2 (en) 2006-05-31 2007-12-13 The Regents Of The University Of California Purine analogs
ES2552471T3 (es) 2007-02-07 2015-11-30 The Regents Of The University Of California Conjugados de agonistas de TLR sintéticos y usos de los mismos
US8772243B2 (en) * 2008-08-20 2014-07-08 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for predicting the response to anti-cancer treatment with an agonist of TLR7 or an agonist of TLR8
WO2010088924A1 (en) * 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
SG173617A1 (en) * 2009-02-11 2011-09-29 Univ California Toll-like receptor modulators and treatment of diseases
US20120083473A1 (en) 2010-09-21 2012-04-05 Johanna Holldack Treatment of conditions by toll-like receptor modulators
KR101250419B1 (ko) 2010-12-16 2013-04-05 강원대학교산학협력단 Tlr 작동제를 포함하는 유방암 방사선 치료 보조제
KR101946499B1 (ko) 2011-04-08 2019-02-11 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 바이러스 감염 치료를 위한 피리미딘 유도체
EP2776439B1 (en) 2011-11-09 2018-07-04 Janssen Sciences Ireland UC Purine derivatives for the treatment of viral infections
EA039373B1 (ru) * 2012-02-08 2022-01-19 Янссен Сайенсиз Айрлэнд Юси Производные пиперидино-пиримидина для лечения вирусных инфекций
CA2874800C (en) 2012-07-13 2021-04-06 Janssen R&D Ireland Macrocyclic purines for the treatment of viral infections
CN112587671A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
NZ705589A (en) 2012-10-10 2019-05-31 Janssen Sciences Ireland Uc Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
AU2013346793B2 (en) 2012-11-16 2018-03-08 Janssen Sciences Ireland Uc Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
KR102225233B1 (ko) 2013-02-21 2021-03-09 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 바이러스 감염의 치료를 위한 2-아미노피리미딘 유도체
MX366481B (es) 2013-03-29 2019-07-09 Janssen Sciences Ireland Uc Deaza-purinonas macrociclicas para el tratamiento de infecciones virales.
MY188071A (en) 2013-05-24 2021-11-16 Janssen Sciences Ireland Uc Pyridone derivatives for the treatment of viral infections and further diseases
CN109369643B (zh) 2013-06-27 2021-05-18 爱尔兰詹森科学公司 用于治疗病毒感染和其他疾病的吡咯并[3,2-d]嘧啶衍生物
EP3027624B1 (en) 2013-07-30 2018-09-12 Janssen Sciences Ireland UC Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections
EP3659603A1 (en) * 2014-01-10 2020-06-03 Urogen Pharma Ltd. Pharmaceutical compositions comprising imiquimod for use in the treatment of carcinoma in situ of the bladder
WO2015104030A1 (en) * 2014-01-10 2015-07-16 Telormedix Sa Pharmaceutical compositions comprising imiquimod for use in the treatment of carcinoma in situ of the bladder
AU2015205753A1 (en) 2014-01-10 2016-07-21 Birdie Biopharmaceuticals Inc. Compounds and compositions for treating HER2 positive tumors
WO2016004876A1 (en) 2014-07-09 2016-01-14 Shanghai Birdie Biotech, Inc. Anti-pd-l1 combinations for treating tumors
CN112587672A (zh) 2014-09-01 2021-04-02 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
KR101729236B1 (ko) 2015-06-01 2017-04-21 (주)노터스생명과학 Tlr7 항진제를 포함하는 비만 또는 간질환 예방 및 치료용 약학 조성물
CN115350279A (zh) 2016-01-07 2022-11-18 博笛生物科技有限公司 用于治疗肿瘤的抗-her2组合
CN106943597A (zh) 2016-01-07 2017-07-14 博笛生物科技(北京)有限公司 用于治疗肿瘤的抗-egfr组合
CN115554406A (zh) 2016-01-07 2023-01-03 博笛生物科技有限公司 用于治疗肿瘤的抗-cd20组合
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms
WO2018002319A1 (en) 2016-07-01 2018-01-04 Janssen Sciences Ireland Uc Dihydropyranopyrimidines for the treatment of viral infections
WO2018060317A1 (en) 2016-09-29 2018-04-05 Janssen Sciences Ireland Uc Pyrimidine prodrugs for the treatment of viral infections and further diseases
CN118515666A (zh) 2017-04-27 2024-08-20 博笛生物科技有限公司 2-氨基-喹啉衍生物
KR20200019226A (ko) * 2017-06-23 2020-02-21 버디 바이오파마슈티칼즈, 인크. 약학 조성물
TW202415645A (zh) 2018-03-01 2024-04-16 愛爾蘭商健生科學愛爾蘭無限公司 2,4-二胺基喹唑啉衍生物及其醫學用途
AU2020292274B2 (en) 2019-06-13 2024-05-23 Hollister Incorporated Reusable urinary catheter products
CA3140908A1 (en) 2019-06-25 2020-12-30 Hollister Incorporated Reusable urinary catheter products
CN112778372B (zh) * 2019-11-11 2025-09-23 苏州泽璟生物制药股份有限公司 咪唑并喹啉取代磷酸酯类激动剂及其制备方法和应用

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL73534A (en) * 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US4938949A (en) * 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5238944A (en) * 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US5736553A (en) * 1988-12-15 1998-04-07 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo 4,5-C!quinolin-4-amine
US5037986A (en) * 1989-03-23 1991-08-06 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo[4,5-c]quinolin-4-amines
US4929624A (en) * 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
NZ232740A (en) * 1989-04-20 1992-06-25 Riker Laboratories Inc Solution for parenteral administration comprising a 1h-imidazo(4,5-c) quinolin-4-amine derivative, an acid and a tonicity adjuster
HU217080B (hu) * 1990-10-05 1999-11-29 Minnesota Mining And Manufacturing Co. Új eljárás imidazo[4,5-c]kinolin-4-amin-származékok előállítására
US5175296A (en) * 1991-03-01 1992-12-29 Minnesota Mining And Manufacturing Company Imidazo[4,5-c]quinolin-4-amines and processes for their preparation
IL105325A (en) * 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
US5395937A (en) * 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
US5352784A (en) * 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US5648516A (en) * 1994-07-20 1997-07-15 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US5525606A (en) * 1994-08-01 1996-06-11 The United States Of America As Represented By The Department Of Health And Human Services Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
DE19505168A1 (de) * 1995-02-16 1996-08-22 Boehringer Mannheim Gmbh Spezifische Lipidkonjugate von Nucleosid-Diphosphonaten und deren Verwendung als Arzneimittel
US5624677A (en) * 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
US5741908A (en) * 1996-06-21 1998-04-21 Minnesota Mining And Manufacturing Company Process for reparing imidazoquinolinamines
US5693811A (en) * 1996-06-21 1997-12-02 Minnesota Mining And Manufacturing Company Process for preparing tetrahdroimidazoquinolinamines
DE19637209B4 (de) * 1996-09-12 2006-12-14 Siemens Ag Verfahren zum Steuern des Antriebsstrangs eines Kraftfahrzeugs und integrierte Antriebsstrangsteuerung
ES2290969T3 (es) * 1996-10-25 2008-02-16 Minnesota Mining And Manufacturing Company Compuestos modificadores de la respuesta inmune para el tratamiento de enfermedades mediadas por th2 y relacionadas.
WO1999024432A1 (fr) * 1997-11-12 1999-05-20 Mitsubishi Chemical Corporation Derives de purine et medicament les renfermant en tant qu'ingredient actif
US6329381B1 (en) * 1997-11-28 2001-12-11 Sumitomo Pharmaceuticals Company, Limited Heterocyclic compounds
US7001609B1 (en) * 1998-10-02 2006-02-21 Regents Of The University Of Minnesota Mucosal originated drug delivery systems and animal applications
US20020058674A1 (en) * 1999-01-08 2002-05-16 Hedenstrom John C. Systems and methods for treating a mucosal surface
US6486168B1 (en) * 1999-01-08 2002-11-26 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
US6245776B1 (en) * 1999-01-08 2001-06-12 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
CZ27399A3 (cs) * 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
US20030187261A1 (en) * 2000-01-07 2003-10-02 Libor Havlicek Purine derivatives, process for their preparation and use thereof
US6533645B2 (en) * 2000-01-18 2003-03-18 Applied Materials, Inc. Substrate polishing article
US6733764B2 (en) * 2000-06-14 2004-05-11 Alain Martin Immunostimulator anti-cancer compounds and methods for their use in the treatment of cancer
JP2004510961A (ja) * 2000-09-15 2004-04-08 ビルコ・ビーブイビーエイ 疾患の処置のための薬物療法を最適化するシステムおよび方法
WO2002030399A2 (en) * 2000-10-11 2002-04-18 Johns Hopkins University Polymer controlled delivery of a therapeutic agent
US20020127224A1 (en) * 2001-03-02 2002-09-12 James Chen Use of photoluminescent nanoparticles for photodynamic therapy
PT1385823E (pt) * 2001-04-09 2007-01-31 Novartis Vaccines & Diagnostic Compostos de guanidino como agonistas do receptor de melanocortina-4 (r-mc4)
ATE404561T1 (de) * 2001-04-17 2008-08-15 Dainippon Sumitomo Pharma Co Neue adeninderivate
DK1401837T3 (da) * 2001-06-29 2005-11-07 Cv Therapeutics Inc Purinderivater som A2B-adenosinreceptorantagonister
EP2336133A1 (en) * 2001-10-30 2011-06-22 Conforma Therapeutics Corporation Purine analogs having HSP90-inhibiting activity
TWI349671B (en) * 2002-09-27 2011-10-01 Dainippon Sumitomo Pharma Co Novel adenine derivative and its use
CN100387710C (zh) * 2003-01-28 2008-05-14 上海三维生物技术有限公司 原发性癌和转移性癌相关的核酸
US20040265351A1 (en) * 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
WO2005016235A2 (en) * 2003-04-14 2005-02-24 The Regents Of The University Of California Combined use of impdh inhibitors with toll-like receptor agonists
US20050059613A1 (en) * 2003-07-08 2005-03-17 Bahram Memarzadeh Compositions and methods for the enhanced uptake of therapeutic agents through the bladder epithelium
WO2005020892A2 (en) * 2003-08-08 2005-03-10 Mitochroma Research, Inc. Pharmaceutical compositions and methods for metabolic modulation
ES2342069T4 (es) * 2003-09-05 2011-01-26 Anadys Pharmaceuticals, Inc. Ligandos de tlr7 para el tratamiento de la hepatitis c.
EP2145888A1 (en) * 2003-09-18 2010-01-20 Conforma Therapeutics Corporation Deazapurine derivatives as HSP90-Inhibitors
FR2863890B1 (fr) * 2003-12-19 2006-03-24 Aventis Pasteur Composition immunostimulante
WO2005084710A2 (en) * 2004-03-02 2005-09-15 Massachusetts Institute Of Technology Nanocell drug delivery system
TWI392678B (zh) * 2004-03-26 2013-04-11 Dainippon Sumitomo Pharma Co 9-取代-8-氧基腺嘌呤化合物
WO2006054129A1 (en) * 2004-11-19 2006-05-26 Institut Gustave Roussy Improved treatment of cancer by double-stranded rna
WO2006065234A1 (en) * 2004-12-10 2006-06-22 University Of Pittsburgh Use of lipid and hydrogel vehicles for treatment and drug delivery
US20070292418A1 (en) * 2005-04-26 2007-12-20 Eisai Co., Ltd. Compositions and methods for immunotherapy
CA2620182A1 (en) * 2005-08-22 2007-03-01 Dennis A. Carson Tlr agonists
JPWO2007034817A1 (ja) * 2005-09-22 2009-03-26 大日本住友製薬株式会社 新規アデニン化合物
EP1939201A4 (en) * 2005-09-22 2010-06-16 Dainippon Sumitomo Pharma Co NEW ADENINE CONNECTION
US20070100146A1 (en) * 2005-11-03 2007-05-03 Trevor Dzwiniel Process for the preparation of imidazo[4,5-c]-quinolin-4-amines
WO2007142755A2 (en) * 2006-05-31 2007-12-13 The Regents Of The University Of California Purine analogs
ES2437871T3 (es) * 2006-07-07 2014-01-14 Gilead Sciences, Inc. Moduladores del receptor tipo toll 7
TW200831104A (en) * 2006-10-04 2008-08-01 Pharmacopeia Inc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
US7902187B2 (en) * 2006-10-04 2011-03-08 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
ES2552471T3 (es) * 2007-02-07 2015-11-30 The Regents Of The University Of California Conjugados de agonistas de TLR sintéticos y usos de los mismos
JP5395068B2 (ja) * 2007-06-29 2014-01-22 ギリアード サイエンシーズ, インコーポレイテッド トール様受容体7の調節物質としてのプリン誘導体およびその使用
EP2200615A1 (en) * 2007-10-16 2010-06-30 Gilead Palo Alto, Inc. A3 adenosine receptor antagonists
SG173617A1 (en) * 2009-02-11 2011-09-29 Univ California Toll-like receptor modulators and treatment of diseases
CN102666541B (zh) * 2009-10-22 2015-11-25 吉里德科学公司 用于治疗特别是病毒感染的嘌呤或脱氮嘌呤的衍生物
EP2563401A1 (en) * 2010-04-30 2013-03-06 Telormedix SA Methods for inducing an immune response
EP2563404B1 (en) * 2010-04-30 2016-09-21 Urogen Pharma Ltd. Phospholipid drug analogs
CN103313725B (zh) * 2010-09-01 2016-06-29 诺华有限公司 免疫增强剂吸附不溶性金属离子
US20120083473A1 (en) * 2010-09-21 2012-04-05 Johanna Holldack Treatment of conditions by toll-like receptor modulators

Similar Documents

Publication Publication Date Title
JP2011511073A5 (enExample)
RU2477723C2 (ru) Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
JP2015520143A5 (enExample)
WO2009099650A4 (en) Treatment of bladder diseases with a tlr7 activator
JP2013507423A5 (enExample)
JP2015512943A5 (enExample)
RU2012104700A (ru) Азабициклосоединение и его соль
JP2014508811A5 (enExample)
JP2013513613A5 (enExample)
JP2015501833A5 (enExample)
JP2012516865A5 (enExample)
JP2015509098A5 (enExample)
JP2009536933A5 (enExample)
RU2016137832A (ru) Соединения для лечения опосредованных комплементом нарушений
JP2014520898A5 (enExample)
JP2008501000A5 (enExample)
JP2004534774A5 (enExample)
JP2013508288A5 (enExample)
JP2016503797A5 (enExample)
JP2014511367A5 (enExample)
JP2009541209A5 (enExample)
JP2013520473A5 (enExample)
JP2006519852A5 (enExample)
JP2012506443A5 (enExample)
JP2012513390A5 (enExample)